EMA Accepts Alvotech and Advanz Pharma's Application for Eylea Biosimilar
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency (EMA) has accepted Alvotech and Advanz Pharma's Marketing Authorization Application for AVT06, a biosimilar to Eylea. The authorization process could be completed by Q3 2025.
August 15, 2024 | 8:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EMA has accepted Alvotech's application for AVT06, a biosimilar to Eylea. The marketing authorization process could be completed by Q3 2025.
The acceptance of the application by EMA is a positive regulatory milestone for Alvotech. If approved, it could lead to new revenue streams starting in Q3 2025.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80